Sulfateq B.V. (ST)
Company websiteGuido Krenning, PhD
Sulfateq BV
g.krenning at sulfateqbv.com
A. de Ruijterlaan 5
9726 GN Groningen
The Netherlands
ORCID: 0000-0001-5850-5667
Google Scholar
Institute profile
Company profile
Guido Krenning earned his biology degree in 2004 from the University of Groningen and completed his PhD in medical sciences at the University Medical Center Groningen in 2009. Following his doctoral studies, he pursued postdoctoral research in organ fibrogenesis at Harvard Medical School, Boston (MA) USA. In 2011, he established his own research group in cardiovascular pathophysiology at the Department of Pathology and Medical Biology, University Medical Center Groningen, Netherlands. In 2022, he transferred his research team to the Department of Clinical Pharmacy and Pharmacology (University Medical Center Groningen), where he is appointed as associate professor of Experimental Pharmacology and Head of Research. In 2016, Guido was appointed Chief Scientific Officer of the privately-held biotech Sulfateq BV (Groningen, Netherlands).
His academic research group operates at the crossroads of biochemistry, molecular biology, pathology, and pharmacology, with the aim of understanding and mitigating mitochondrial dysfunction to prevent and treat noncommunicable diseases. Guido's scientific curiosity lies in how the mitochondrion senses and deals with environmental and cellular stresses to effectively respond to a wide array of threats while maintaining cellular homeostasis and how these mechanisms are deranged in chronic disease. His team investigates mitochondrial (dys)function in the context of various diseases, primarily focusing on cardiometabolic diseases and neurodegenerative diseases.
His biotech research centralizes around the identification and targeting of mitochondrial drug targets to effectively mitigate mitochondrial dysfunction and to maintain cell/tissue/organ homeostasis. Central to these research activities are identification and validation of mitochondrial drug targets, the identification and optimization of small molecule compounds with drug-like behaviours and establishing proof-of-concept for their therapeutic efficacy in a diversity of preclinical chronic disease models.
His research has been funded by Innovational Research Incentives from the Netherlands Organization for Scientific Research (VENI 2009, VICI 2015), Career Development Grant from the Dutch Kidney Foundation (2015), Research and Training Network (GRK) grants from the German Research Counsil (GRK1874, 2012, 2017) and various public-private partnerships. He received the Pauline van Wachum Award from the Dutch Society of Tissue Engineering and Regenerative Medicine (NBTE) for best PhD thesis in Regenerative Medicine (2009).